Bristol Myers Squibb Acquires Karuna Therapeutics for $14 Billion to Boost Neurological Drugs Market


  • Bristol Myers Squibb (NYSE:) set to acquire neuroscience-drug developer Karuna Therapeutics (NASDAQ:) for $14 billion.
  • Agreement details Bristol Myers Squibb paying $330 per share in cash, including Karuna’s current $1.3 billion cash holding.
  • The acquisition impacts Bristol Myers Squibb’s share value whilst providing a 50% premium on Karuna shares.
  • This strategic acquisition is scheduled for completion in H1 of next year, and will bolster Bristol Myers Squibb’s hold on the psychiatric and neurological drugs market.
  • Karuna’s portfolio highlight, KarXT, is an experimental drug under FDA review for schizophrenia treatment.

Pharmaceutical giant Bristol Myers Squibb (NYSE:) will acquire neuroscience-drug developer, Karuna Therapeutics (NASDAQ:), in a deal worth $14 billion, according to recent news reports.

As per the specifics of the agreement, Bristol Myers Squibb will purchase Karuna’s shares at $330 each in cash. This sum also encompasses the $1.3 billion cash currently held by Karuna, reports Wall Street Journal.

Bristol Myers Squibb Share Impact

Following this news, Bristol Myers Squibb’s shares took a dip of 2.2% in pre-market activity. Previous close on Karuna shares stood at $215.19, rendering the acquisition a substantial premium of over 50%.

Strategic Acquisition

The acquisition, slated for closure in the first half of the forthcoming year, personifies a key strategy for Bristol Myers Squibb to solidify its foothold in the psychiatric and neurological drugs market.

Karuna’s Key Drug

A critical asset for Karuna is their experimental drug, KarXT. This drug is currently undergoing a review process with the Food and Drug Administration (FDA) for approval as a treatment for schizophrenia.

The potential alterations in share value brought on by this acquisition can substantially impact Forex trading, particularly for assets linked to Bristol Myers Squibb and Karuna Therapeutics.

PIP Penguin